Europe reviews Valneva’s chikungunya vaccine, Pg 7

The Hindu | May 9, 2025

Key Highlights

• The European Medicines Agency (EMA) is reviewing Valneva’s chikungunya vaccine (Ixxchiq) due to reports of serious side effects in older adults.
• Temporary suspension of the vaccine in people aged 65 and above.
• 17 serious adverse events, including 2 deaths, reported globally in individuals aged 62–89.
• Company is cooperating with health authorities; causal link not yet established.

Detailed Insights

• EMA’s safety committee has triggered the review following a pattern of adverse reactions in the elderly.
• The vaccine is being closely monitored for further data on safety and efficacy, especially in older populations.
• Decision reflects regulatory precaution to uphold public health safety across EU nations.
• The events highlight the challenges in post-approval surveillance of novel vaccines.

Scientific/Technical Concepts Involved

• Chikungunya: A mosquito-borne viral disease causing fever and joint pain.
• Adverse Events Following Immunization (AEFI): Unintended medical occurrences after vaccination, not necessarily causally related.
• EMA (European Medicines Agency): Regulatory authority overseeing drug and vaccine safety in EU countries.

Significance

• Raises concerns about vaccine safety in elderly populations, a key demographic in public health policy.
• May impact global rollout and public confidence in new vaccines.
• Demonstrates the importance of pharmacovigilance and adaptive regulation in vaccine governance.
• Adds to the global dialogue on ethical, safe vaccine dissemination and international coordination.

Mains Mock Question:

Examine the role of international regulatory bodies like the European Medicines Agency in ensuring vaccine safety. How should countries balance rapid vaccine development with post-approval monitoring mechanisms? (15 marks)